Complement slows heart cells by Van Epps, Heather L.
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The complement activation product 
C5a prevents heart cells from contract-
ing, according to Niederbichler and 
colleagues on page 53. This finding may 
help explain the cardiac dysfunction 
commonly seen in patients with septic 
shock—a disease caused by bacterial in-
fections that is characterized in part by 
the robust activation of the comple-
ment system.
A central component of septic shock 
is decreased heart function, which de-
prives tissues of oxygen and nutrients 
and can progress to fatal multiorgan 
failure. Past studies have shown that a 
“myocardial depressant factor” is re-
leased into the serum during sepsis, 
with most studies attributing the de-
pressant activity to proinflammatory 
cytokines released by immune cells re-
sponding to the infection.
Robust activation of the comple-
ment cascade is another hallmark of bac-
terial sepsis. Complement is a series of 
plasma proteins that helps destroy infect-
ing microbes and attracts immune cells 
to sites of infection. C5a activates im-
mune cells, such as neutrophils, which 
can then attack and kill the invading 
bacteria. But too much C5a can be dele-
terious, as blocking the protein or its re-
ceptor increases survival in rodent 
models of septic shock. This group pre-
viously showed that excessive C5a some-
how prevents the activation of MAP 
kinase signaling in neutrophils, which 
jams up downstream signals and robs the 
cells of their ability to destroy bacteria.
The receptor for C5a (C5aR) is also 
expressed on airway cells, including 
bronchial epithelial cells and smooth 
muscle cells, but a link between comple-
ment and sepsis-induced cardiac dys-
function had not been directly 
investigated. Niederbichler and col-
leagues now show that cardiomyocytes, 
which help control heartbeat, also ex-
press C5aR—possibly to increase blood 
flow in response to infection or stress.
But as with neutrophils, too much 
C5a was bad for cardiomyocytes. Treat-
ment of cardiomyocytes with high con-
centrations of C5a impaired their ability 
to contract. Blocking the interaction be-
tween C5a and its receptor in rats re-
lieved the sepsis-induced drop in blood 
pressure. The authors are now investi-
gating the molecular pathways that link 
C5aR signaling to the contractile ma-
chinery of the cell; they suspect that ex-
cessive C5a might induce a signaling 
paralysis in cardiomyocytes similar to 
that seen in neutrophils. 
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Cytokine therapy post–heart attack restores the expression of gap 
junction proteins and thus restores electrical connections between 
heart cells, according to a new study by Kuhlmann and colleagues 
(page 87). These heart cells, with better electrical connections, are 
able to pump with a more normal rhythm.
Restoring the function of damaged heart tissue is a new 
approach to the treatment of myocardial infarctions, or heart 
attacks. The scar tissue from heart attacks creates a roadblock for 
electrical conduction and can cause the heart to beat erratically. 
Indeed, erratic heartbeats—or arrhythmias—are the primary cause 
of death in patients who have had heart attacks.
Heart attack treatments range from blood-thinning and 
cholesterol-lowering drugs, which reduce the likelihood of 
developing blocked arteries, to implanted defibrillators that shock 
erratically beating hearts into line. But the idea of repairing damaged heart tissue is new. One promising repair 
approach involves the intravenous injection of two cytokines—G-CSF (granulocyte colony-stimulating factor) and 
SCF (stem cell factor)—which mobilize stem cells from the bone marrow (BM). Early studies suggested that these 
stem cells travel to the damaged heart and differentiate into functional heart cells called cardiomyocytes. Other 
studies, however, found no evidence that stem cells can become cardiomyocytes.
Kuhlmann and colleagues now confirm that G-CSF/SCF treatment in mice with heart damage causes BM-derived 
cells to enter the heart, but they show that virtually none of these cells become bona fide heart cells. The benefit of 
this treatment—which improved the heart’s pump function and protected against induced arrhythmias—instead 
correlated with enhanced expression of the gap junction protein connexin 43 on the surface of heart cells adjacent to 
the injured tissue. The expression of connexin 43, which provides the electrical connection between neighboring cells, 
is decreased after heart injury, thus reducing the conductive capacity between cells.
The connexin-inducing effect of G-CSF might be direct, as cardiomyocyte expression of the G-CSF receptor 
was increased in response to injury. But this possibility is difficult to test in vitro, as mouse cardiomyocytes grow 
poorly in culture. The authors are also investigating G-CSF–independent signaling pathways that induce the 
expression of connexin 43 in other cell types. 
G-CSF treatment restores the expression of connexin 43 on 
cardiomyocytes near areas of heart attack–induced damage (arrows).
G-CSF treatment restores the expression of connexin 43 on 
cardiomyocytes near areas of heart attack–induced damage (arrows).